CTOR Citius Oncology, Inc. Operatsion rentabellik

citiusonc.com (CTOR) kompaniyasining korporativ logotipi

Operatsion marja ko'rsatkichi Citius Oncology, Inc. (CTOR) kompaniyasining samaradorlik dinamikasini namoyish etadi, bunda -665.60 ko'rsatkichning joriy qiymatidir. Citius Oncology, Inc. (CTOR) ishlab chiqarish va sinovlarni tashqi hamkorlarga topshirish orqali kapital xarajatlarni minimallashtiradi. Kam uchraydigan limfatik patologiyalar bo'yicha ixtisoslashuv va orfan dori maqomi ushbu nishani takrorlanishdan himoya qiladi. Joriy daromad teri T-hujayrali limfomasini davolash vositasining bozorga chiqarilishi hisobiga shakllantirilmoqda.

CTOR - Citius Oncology Operatsion foyda normasi 14.08.2024 - 20.11.2026 oraligʻida

Citius Oncology, Inc. (CTOR) kompaniyasining tahliliy kesimlari

Kompaniyaning har tomonlama tahlili:CTOR, citiusonc.com
Citius Oncology Inc asosiy tovari

Operatsion marja asosiy faoliyatdan olingan foydaning umumiy daromadga nisbatan ulushini aks ettiradi. Ushbu ko'rsatkich soliqlar va qarz majburiyatlarini hisobga olishdan oldin xarajatlarni boshqarish samaradorligini o'lchaydi. Citius Oncology, Inc. (CTOR) uchun shaxsiy ishlab chiqarish zavodlarining yo'qligi va sinovlarning autsorsing qilinishi kapital xarajatlarni minimallashtiradi, bu esa bevosita ushbu metrikaning hisob-kitobiga ta'sir qiladi. Operatsion samaradorlikdagi tendentsiya bunday moslashuvchan biznes modelning daromadliligini baholash imkonini beradi. Ushbu ko'rsatkichning o'sishi kompaniyaning barqarorligini tasdiqlaydi.

Citius Oncology, Inc. raqobatchilari

Operatsion rentabellik BeiGene Ltd|Halozyme Therapeutics - Operatsion foyda marjasi|Sotuvning operatsion marjasi RVMD (Revolution Medicines Corp)|Operatsion foyda koeffitsiyenti AAPG|Operatsion rentabellik CG Oncology Therapeutics CGON|Operatsion foyda normasi URGN|BCAX: Sotuvning operatsion marjasi|PSNL: Operatsion rentabellik|Erasca (ERAS) - Operatsion rentabellik|DCTH - Operatsion faoliyat rentabelligi|YMAB (Y-mAbs Corp) - Operatsion marja|Sotuvning operatsion marjasi Aura Biosciences (AURA)|Operatsion rentabellik Candel Therapeutics Inc. (CADL)|Sotuvning operatsion marjasi Accuray, Inc. ARAY|Operatsion rentabellik sellaslifesciences.com SLS|Operatsion foyda normasi ACTU|TuHURA Biosciences Inc. - Operatsion marja|TARA - Operatsion marja|FATE (Fate Therapeutics) - Sotuvning operatsion marjasi|Sotuvning operatsion marjasi Aadi Bioscience, Inc.|Sotuvning operatsion marjasi TCRX|Operatsion rentabellik CSBR|Operatsion marja XBIT|Operatsion faoliyat rentabelligi CEL-SCI Corp.|Operatsion rentabellik ostherapies.com OSTX|RADX: Operatsion foyda bo'yicha sotuv rentabelligi|ARTV: Sotuvning operatsion marjasi|ANL (Adlai Nortye) - Operatsion foyda bo'yicha sotuv rentabelligi|Veru (VERU) - Operatsion rentabellik|Sotuvning operatsion marjasi Tempest Therapeutics Inc|Operatsion rentabellik Xilio Therapeutics|Operatsion foyda bo'yicha sotuv rentabelligi RENB (Renovaro Inc.)|Operatsion rentabellik Mural Oncology PLC (MURA)|Operatsion marja Kairos Pharma (KAPA)|Operatsion rentabellik onkuretherapeutics.com OKUR|GDTC: Operatsion foyda bo'yicha sotuv rentabelligi|CRIS: Sotuvning operatsion marjasi|apollomicsinc.com (APLM) - Sotuvning operatsion marjasi|THAR: Operatsion marja|Sotuvning operatsion marjasi Advanced Biomed Inc.|Sotuvning operatsion marjasi GNPX|Operatsion foyda bo'yicha sotuv rentabelligi CLDI (Calidi Biotherapeutics)|Operatsion marja SBFM|Xenetic Biosciences, Inc. - Operatsion foyda bo'yicha sotuv rentabelligi|Operatsion rentabellik Salarius Pharmaceuticals SLRX|Operatsion marja purple-biotech.com PPBT|AONC - Operatsion rentabellik|BGNE: Operatsion rentabellik|CKPT: Operatsion marja|Elevation Oncology - Operatsion foyda normasi|ICAD (iCAD) - Operatsion marja|IKNA: Operatsion foyda normasi|Operatsion rentabellik Notable Labs (NTBL)|VIRX (Viracta Therapeutics, Inc.) - Operatsion foyda normasi|Operatsion rentabellik MorphoSys Corporation MOR|NAYA: Operatsion foyda bo'yicha sotuv rentabelligi|Ascentage Pharma Group International - Operatsion marja